MCIA investigations shine further light on Australia’s medicinal cannabis industry

In October MCIA released data obtained from the Office of Drug Control that revealed the volume of medicinal cannabis produced by Australian cultivators, along with volumes of imports and exports. MCIA has now obtained data from TGA that sheds light on the nature of products sold in Australia.

Continue reading “MCIA investigations shine further light on Australia’s medicinal cannabis industry”

MCIA Workshop: Tips for successfully engaging with Human Research Ethics Committee

On 28 October 2022 held a workshop on “Tips for successfully engaging with Human Research Ethics Committee”. This workshop was designed to provide a forum for participants from across the medicinal cannabis industry, and particularly medicinal cannabis companies and research organisations, to discuss approaches to successfully engaging with HREC in the area of clinical trials involving unregistered medicinal cannabis therapeutic goods.

Continue reading “MCIA Workshop: Tips for successfully engaging with Human Research Ethics Committee”

MCIA Virtual Workshop: Tips for successfully engaging with Human Research Ethics Committee

This workshop is designed to provide a forum for participants from across the medicinal cannabis industry, and particularly medicinal cannabis companies and research organisations, to discuss approaches to successfully engaging with HREC in the area of clinical trials involving unregistered medicinal cannabis therapeutic goods.

MCIA is supporting this to assist in enabling and encouraging robust clinical research in the sector.

Date:        28 October 2022
Time:       11:00am – 1.00pm (AEST)
Virtual:    Zoom link will be provided when you register

The workshop will cover:

  • Sponsor obligations and responsibilities
  • Botanical drug product and quality control
  • Preclinical evidence
  • Trial design

Facilitator:

  • Dr Melinda Thompson, Head of Regulatory Affairs & Quality Systems Source Certain and Chair of MCIA Research Working Group

Presenters include:

  • Professor Andrew McLachlan, Head of School & Dean of Pharmacy, University of Sydney
  • Biljana Georgievska, EVP Commercial, Nucleus Network
  • Dr Anastasia Suraev, The Lambert Initiative

Please register below if you would like to attend and you will receive a confirmation email containing information about joining the meeting.

ACannabis 2023: Growing The Industry Through Research, Collaboration and Innovation.

ACannabis is back

ACannabis has established itself as a professional, credible industry event on the Australian medicinal cannabis calendar.  Speakers, partners and delegates continue to rate the conference highly for format, content and organisation and we can’t wait to come back face to face in 2023.

Continue reading “ACannabis 2023: Growing The Industry Through Research, Collaboration and Innovation.”

MCIA are deeply saddened to hear of the passing of Dame Olivia Newton-John

Olivia was an inspirational and vocal advocate for medicinal cannabis.  She knew the important role medicinal cannabis could play in the journey of a cancer patient and was passionate about increased patient access.  

When MCIA launched, she was excited to see the industry come together to discuss these important issues to ensure all patients had access to medicinal cannabis. 

Continue reading “MCIA are deeply saddened to hear of the passing of Dame Olivia Newton-John”

MCIA Networking Event: Understanding Clinical Trials and Insurance Requirements

Please join MCIA and industry colleagues for a fireside chat and networking function. Daniel Rooney (Insurance broker, Marsh) will be in conversation with Will Clarke (Underwriter, NewLine) to discuss Understanding Clinical Trials and Insurance Requirements. Will and Daniel will discuss the in’s and outs of clinical trials, where claims typically occur and how to make sure you have the right protection in place

Continue reading “MCIA Networking Event: Understanding Clinical Trials and Insurance Requirements”